Saturday 17 October 2026
Export GRFS’s income statement to Excel — free account
Grifols, S.A.
GRFS Healthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024. In the quarter to June 2026, revenue grew 5.76%, EPS grew 466.9%, free cash flow grew 300.5% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
7.64
0.10
+1.33%
Follow GRFS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
24.51 | 10.35 | 8.88 | — |
P/S ratio |
0.84 | 0.75 | 0.63 | — | |
P/FCF ratio |
14.04 | 9.85 | 9.06 | — | |
P/Operating CF |
17.58 | 13.70 | 42.39 | — | |
P/B ratio |
0.78 | 0.74 | 0.59 | — | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | — | |
EV/Sales |
2.10 | 1.91 | 1.84 | — | |
EV/EBITDA |
9.61 | 8.51 | 8.23 | — | |
EV/Operating CF |
16.37 | 13.76 | 13.57 | — | |
EV/FCF |
35.25 | 25.24 | 26.37 | — | |
Quick Ratio |
0.85 | 0.80 | 0.76 | 0.70 | |
Current Ratio |
2.48 | 2.51 | 2.47 | 2.37 | |
Net Debt/EBITDA |
19.13 | 22.27 | 25.10 | 0.00 | |
Debt/Assets |
48.80% | 48.92% | 48.16% | 46.57% | |
Debt/Equity |
1.28 | 1.27 | 1.23 | 1.17 | |
Asset Turnover |
0.35 | 0.38 | 0.38 | 0.00 | |
Operating CF/Net income |
2.63 | 4.20 | 1.51 | 0.00 | |
Capex/Depreciation |
(1.02) | (1.02) | (0.87) | (1.09) | |
Interest Coverage |
2.27 | 1.68 | 1.81 | — | |
Research and Development Expense of Revenue |
5.20% | 6.87% | 5.29% | — | |
Selling, General and Administrative Expense of Revenue |
15.28% | 14.10% | 16.53% | — | |
Intangible Assets out of Total Assets |
0.53 | 0.49 | 0.53 | 0.49 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | |
Graham Net Nets |
(1.19) | (1.25) | (1.50) | — | |
Graham Number |
0.00 | 16.03 | 0.00 | — | |
Earnings Yield |
4.08% | 9.66% | 11.26% | — | |
Free Cash Flow Yield |
7.12% | 10.15% | 11.04% | — | |
Revenue per Share |
0.00 | 3.39 | 0.00 | — | |
Operating CF per Share |
0.00 | 0.68 | 0.00 | 0.00 | |
Capex per Share |
0.00 | (0.20) | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.48 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 1.43 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 12.64 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 12.64 | 0.00 | 0.00 | |
Free Cash Flow |
259.44 | 327.96 | 23.41 | 128.91 | |
Working Capital |
3,733.38 | 3,456.43 | 3,663.35 | 3,568.33 | |
Capital Expenditures |
(130.72) | (136.42) | (105.34) | (134.18) | |
Net Current Asset Value |
(8,132.08) | (7,959.40) | (8,165.88) | (7,912.18) | |
EV/EBIT |
11.94 | 11.59 | 11.21 | — | |
Capex to Sales |
0.06 | 0.06 | 0.05 | 0.00 | |
Price to Operating Income |
4.76 | 4.52 | 3.85 | — | |
| Other line items | |||||
Average Receivables |
1,037.27 | 960.73 | 1,031.48 | 997.85 | |
Average Payables |
— | 865.12 | — | 968.46 | |
Average Inventory |
3,907.92 | 3,764.44 | 3,880.29 | 3,929.75 | |
Average Assets |
23,606.37 | 22,303.03 | 22,800.10 | 22,899.16 | |
Average Common Equity |
8,878.00 | 7,242.39 | 8,960.87 | 8,951.89 |
Columns are period end dates